维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Todd M.Tuttle"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?显示文摘Background:Intrahepatic cholangiocarcinoma(ICC)is rare with limited evidence-based guidelines.This retrospective study evaluates the use of chemotherapy in patients with resected ICC.Methods:The Surveillance Epidemiology and End Results(SEER)program database was used to identify patients with resected ICC.Patients were stratified by date of diagnosis(2000-2004,2005-2009,2010-2014),T,and N stage.Multivariable logistic regression models identified predictors of chemotherapy use.Kaplan-Meier and Cox proportional hazard models were used to identify survival trends.Results:One thousand and two hundred twenty-three patients met inclusion criteria.Chemotherapy utilization increased over time(33%to 41%,P≤0.05).Chemotherapy use increased in lymph node(LN)positive patients[32%to 60%in 2010-2014;(P≤0.05)and T3/T4 disease(40%to 60%in 2010-2014;P≤0.01)],but not in patients with LN negative or T1/T2 disease.LN positivity was associated with utilization of chemotherapy in 2005-2009 and 2010-2014.Overall survival increased from 32 to 41 months(P≤0.05).In LN positive patients,chemotherapy was associated with a decreased hazard ratio of death(P≤0.05)and T3/T4 disease was associated with an increased hazard ratio of death(P≤0.05).Conclusions:Adjuvant chemotherapy use in ICC has increased.More LN positive or patients with T3/T4 tumors are receiving chemotherapy,which may explain the improvement in overall survival.	Ariella M.Altman Scott Kizy Schelomo Marmor Jane Y.C.Hui Todd M.Tuttle Eric H.Jensen Jason W.Denbo	2020	Hepatobiliary Surgery and Nutrition2020，9，5：	10

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费